By demonstrating how YY1 maintains prognostic value in a distinct population, we contribute valuable insights validating YY1 as a biomarker and emphasize the relevance of incorporating advanced pathology tools such as TMAs and DP into future translational cancer research. This evidence concerns the gene YY1 and cancer.